#### Implementation of the 2021 molecular ESGO/ESTRO/ESP risk 1 groups in endometrial cancer 2

3

Sara Imboden<sup>2</sup>, Denis Nastic<sup>1</sup>, Mehran Ghaderi<sup>1</sup>, Filippa Rydberg<sup>1</sup>, Franziska Siegenthaler<sup>2</sup>, 4

- 5 Michael D Mueller<sup>2</sup>, Tilman T Rau<sup>3</sup>, Elisabeth Epstein<sup>4</sup>, Joseph W. Carlson<sup>1\*</sup>
- 6
- 7 <sup>1</sup> Department of Oncology-Pathology, Karolinska Institutet, and Department of Pathology and 8 Cytology, Karolinska University Hospital, Stockholm, Sweden
- 9 <sup>2</sup> Department of Obstetrics and Gynecology, Bern University Hospital and University of
- 10 Bern, Bern, Switzerland
- <sup>3</sup> Institute of Pathology, University of Bern, Bern, Switzerland 11
- <sup>4</sup> Department of Clinical Science and Education, Karolinska Institutet, and Department of 12
- 13 Obstetrics and Gynecology, Södersjukhuset, Stockholm, Sweden
- 14
- 15 \* Corresponding author
- 16 Joseph W. Carlson
- 17 Radiumhemmet P1:02
- 18 Dept of Pathology and Cytology
- 19 Karolinska University Hospital – Solna campus
- 20 17176, Stockholm. SWEDEN
- 21 Tel: +46 (0)76 1130912
- 22 FAX: +46 (0)8 517 745 24
- 23 Email: joseph.carlson@ki.se (JC)
- 24 Twitter handle: @joseph carlson
- 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 Funding information and Acknowledgments

- 27 The funders had no role in study design, data collection and analysis, decision to publish, or
- 28 preparation of the manuscript. Funding sources are: Bernese Cancer League
- 29 (https://bern.krebsliga.ch/), Swiss National Science Foundation
- 30 (IZSE70\_177073)http://www.snf.ch/; Avtal om Läkarutbildning och Forskning (ALF), ALF-
- 31 Stockholm County (grant no 550411)https://ki.se, Cancer research funding from
- 32 'Radiumhemmet' Stockholm, Sweden (grant no 154112) <u>https://www.rahfo.se</u>, Magnus
- 33 Bergvalls Stiftelse, Cancerfonden, and Foundation for clinical-experimental cancer research.

#### 35 ABSTRACT

#### 36 Introduction

In 2021, a joint ESGO/ESTRO/ESP committee updated their evidence-based guidelines for
endometrial cancer, recommending a new risk grouping incorporating both clinicopathologic
and molecular parameters. We applied the new risk grouping and compared the results to those
of the prior 2016 clinicopathologic system.

#### 41 Materials and methods

We classified molecularly a cohort of 604 women diagnosed with endometrial cancer using immunohistochemistry for TP53 and MMR proteins on a tissue microarray, as well as Sanger sequencing for *POLE* mutations. These results, combined with clinicopathologic data, allowed the patients to be risk grouped using both the new 2021 molecular/clinicopathologic parameters and the prior 2016 clinicopathologic system. In addition, clinical treatment and outcome data were collected from medical records.

#### 48 **Results**

49 The application of the 2021 molecular markers shows Kaplan-Meier curves with a significant 50 difference between the groups for all survival. Molecular classification under the 2021 51 guidelines revealed a total of 39 patients (39/594, 7%) with a change in risk group in relation 52 to the 2016 classification system: the shift was alone due to either P53abn or POLEmut 53 molecular marker. In order to ensure correct 2021 molecular risk classification, not all patients 54 with endometrial cancer need a molecular diagnostic: 386 (65.0%) cases would need to be 55 analyzed by TP53 IHC, only 44 (7.4%) by MMR IHC and 109 (18.4%) POLE sequencing 56 reactions.

#### 57 **Conclusion**

Application of the 2021 molecular risk groups is feasible and shows significant differences in
 survival. IHC for TP53 and MMR and applying POLE sequencing is only needed in selected

cases and leads to shifting risk groups both upward and downward for a sizeable number ofpatients.

62

63 Keywords: endometrial cancer, genomic subgroups, risk group, MMR, POLE, P53

64

65 Abbreviations: EC, endometrial cancer; LVSI, lymphovascular space invasion; POLE,

66 polymerase epsilon; TGCA, The Cancer Genome Atlas; TMA, tissue microarray; OS, overall

67 survival, DSS, disease-specific survival, RFS, recurrence-free survival, IHC,

68 Immunohistochemistry, ESGO, European Society of Gynecological Oncology, ESTRO,

69 European Society for Radiotherapy and Oncology, ESP, European Society of Pathology.

70

### 72 INTRODUCTION

73 In January 2021 the European Society of Gynecological Oncology (ESGO), the European 74 Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology 75 (ESP) published updated guidelines for risk group determination in endometrial cancer, 76 integrating both molecular diagnostics and clinicopathologic variables, with the goal of 77 improving patient treatment[1]. These molecular prognostic risk groups represent a 78 revolutionary change in the management of women with endometrial cancer (EC) and will 79 require a total reorientation of how these patients are diagnosed and treated. Prior to the 80 issuance of these guidelines, prognostic risk groups were based on postoperative 81 clinicopathologic findings such as tumor histology, stage of disease, grade, and lymphoyascular 82 space invasion (LVSI) [2-5]. The new 2021 molecular risk groups are a hybrid of 83 clinicopathologic findings and molecular markers. The new risk grouping serves as the basis 84 for patient management, especially the use and type of adjuvant therapy. However, 85 implementation of the 2021 molecular risk groups carries with it numerous challenges. These 86 include, but are not limited to, (1) introduction of molecular testing for a relatively common 87 tumor that is treated at both specialized cancer centers and smaller, more community-based, 88 centers, (2) interpretation of molecular diagnostic results by clinical teams that may not have 89 encountered them previously, and (3) movement of patients between risk groups in sometimes 90 surprising ways, which may cause worry and concern by the patient and care team.

91 The molecular understanding of EC has seen an incredible evolution over the past decade. In 92 2014, The Cancer Genome Atlas (TCGA) [6] developed an integrated genomic classification 93 of endometrial cancer (EC), dividing cases into four genomic subgroups: (1) copy number high 94 "serous-like," (2) copy number low "endometrioid-like," (3) polymerase epsilon (*POLE*) 95 ultramutated, and (4) microsatellite unstable "MSI (hypermutated)", with each group exhibiting 96 a different progression-free survival. Since then, numerous research groups have explored ways

97 to introduce a clinically applicable molecular-based classification system for EC[7–15]. These 98 molecular markers have been evaluated in isolation, as well as in classification schema, in order 99 to compare them with traditional clinicopathologic based systems. Finally, in the 5<sup>th</sup> addition 100 of the WHO Classification of Female Genital Tumors, published in September 2019, the 101 molecular classification is integrated, finalizing the definite place of molecular markers in the 102 diagnosis of EC [16].

The primary objective of the current study was to evaluate the implementation of the 2021 ESGO/ESTRO/ESP molecular risk groups in a large and unselected EC patient cohort. A second objective was to compare the new risk groups with the 2016 clinicopathologic only, non-molecular risk groups. A third objective was to identify challenges to implementation, with the goal of providing concrete guidance to clinics, large and small, implementing this system [2,17].

109

#### 110 MATERIALS AND METHODS

#### 111 **Patient cohort and clinical data**

The study was approved by the local ethics boards in Stockholm and in Bern (2016/362 and 2018-00479, respectively); ethics approval for the bio banking of tissue was granted from the regional biobank review board in each country. All women provided written informed consent for the use of their bio banked tissue and clinical data for research purposes.

This is a retrospective cohort study; the women were selected without reference to tumor type and therefore can be said to represent a population-based cohort of all EC women during the years 2004-2015. A cohort of 349 women diagnosed with EC from Karolinska University Hospital (2011-2015) and 255 women from Bern University Hospital (2004-2015) was established (KImBer cohort). Clinical and radiological data, medical history, and treatment data as well as pathology-associated parameters were obtained through a review of digital medical

records and pathology reports. Follow-up data on recurrence and survival are available through standardized databases and follow-up controls in both clinics. All pathology slides were reviewed by reference pathologists (Karolinska cases, DN, JC, and Bern cases, TR) to confirm grade and histotype.

126

#### 127 Molecular classification: 2021 ESGO/ESTRO/ESP

128 Molecular analysis was applied following the WHO Classification of Tumours, 5th Edition, 129 Volume 4: Female Genital Tumours. Cases were classified as POLEmut, MMRd, NSMP, and 130 p53abn [7–10,18–21]). We constructed a TMA (tissue microarray) upon which we performed 131 immunohistochemistry for p53 and MMR proteins MLH1, MSH2, MSH6, and PMS2. 132 Mismatch repair protein deficiency (MMRd) was defined as loss of nuclear staining in at least 133 one out of the four MMR proteins. P53 aberrant protein expression (p53abn) was defined as 134 either complete loss of nuclear protein expression or strong homogenous nuclear 135 overexpression.

#### 136 **POLE sequencing**

To identify *POLE* (ultramutated) tumors, DNA was isolated from two 1 mm core punches of
formalin-fixed paraffin-embedded tumor tissue using a commercial DNA extraction kit
(PerkinElmer chemagen Technology, chemangic protocol name: DNA formalin-fixed paraffinembedded external lysis VD101124.che) according to the manufacturer's protocol. All EC cases
were analyzed for mutations of *POLE* gene (NM.006231) exons 9-14 by Sanger sequencing.
Details of primers and interpretation of mutations has been published previously[15].

A tumor was considered *POLE* mutated (*POLE*mut) if sequencing proved the existence of a
hotspot mutation in the exonuclease domain *POLE*, as described in our publication on *POLE*mut tumors [15] and verified by Gilks et al [22].

# 146 Multiple classifiers

- 147 Analyzing tumors for p53, MMR and *POLE* can reveal defects in multiple molecular markers.
- 148 These tumors were classified as recommended in the 2021 ESGO/ESTRO/ESP system (i.e.,
- 149 first *POLE*mut, then MMRd, then p53abn).
- 150

#### 151 **Prognostic risk grouping**

The patients were divided into two prognostic risk groups: (1) addition of the new 2021
ESGO/ESTRO/ESP molecular classification system and (2) the 2016 clinicopathologic system
only.

A flow chart was developed, that allowed an identification of each patient into a risk categoryby using as few supplementary tasting as possible.

#### 157 STATISTICAL ANALYSIS

To address the first objective of our study, prognostic risk groups were examined looking at overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) using both Kaplan–Meier plots with log-rank significance testing and Cox proportional-hazards regression models.

Associations between molecular classifiers and other variables such as demographic and clinicopathological factors were tested using non-parametric tests. T-test and ANOVA were used for continuous variables; log-rank test, chi-square, and Fisher's exact test were used for categorical variables.

166 A statistical significance level of 0.05 was used. IBM SPSS software version 24.0 was applied.167

#### 168 **RESULTS**

### 169 General clinicopathological characteristics

Initially, 604 women were included in this study. Molecular classification (one or more
molecular markers) was not possible for 10 of them; these women were therefore excluded

- 172 from the analyses. At initial diagnosis, mean and median ages were 66.1/67 (range 31-93) years,
- and BMI was 29/27.6 (range 16.4-58.6). Only 53 (8.9%) of the women were premenopausal at
- the time of initial diagnosis. Most of the women were either para 2 (32.5%) or nulliparous
- 175 (23.6%) (range 0-9).

## 176 Application of Molecular Markers

- 177 Results of the molecular classification and associations with clinicopathological characteristics178 are summarized in Table 1.
- 179 Only three clinicopathological factors showed no significant association with the molecular
- 180 classification (BMI, myometrial invasion and lymph node status: p values of 0.68, 0.08, and
- 181 0.2 respectively). Or else the groups differ significantly in their clinical features.

#### 182 **2021 ESGO/ESTRO/ESP Molecular Prognostic Risk Groups**

- 183 Application of the 2021 molecular prognostic risk groups to the cohort revealed the
- 184 distribution in the five risk groups: low risk N=243(40.9%), intermediate risk N=84 (14.1%)
- 185 high-intermediate N=89 (15.0%) high risk N=148 (24.9%) and advanced N=30 (5.1%). A
- 186 detailed comparison of the 2021 molecular with the 2016 clinicopathologic only prognostic

187 risk groups is shown as a cross table (Table 2).

188

189 A total of 39 patients changed group in the new classification. In 17 patients, there is a shift

190 upward due to classification as p53abn. In 22 patients, there is a shift downward due to

191 classification as POLEmut. The shift of patients between prognostic risk groups, as well as

the distribution of the molecular subtypes within the prognostic groups, is shown in Figure 1.

- 193 Additionally, three patients show advanced, FIGO Stage 3 disease and POLE mutation. All
- three patients had hotspot mutations (S297F, V411L and P286R). In the 2021 molecular risk
- 195 groups, these patients are not clearly classifiable and were left in the high / advanced risk group.

# 197 Double and Triple Classifiers

- 198 In this cohort, 47 patients had tumors with multiple molecular aberrations. There were 45
- 199 tumors with double aberrations (32 with P53abn and MMRd, 10 with P53abn and POLEmut,
- 200 2 with MMRd and POLEmut). There were 2 cases with three aberrations (i.e. P53abn,
- 201 POLEmut and MMRd).
- A total of 126 tumors were P53abn, but of these 10 had a POLEmut and 32 were MMRd (2
- 203 both). Thus, only 86 tumors were finally classified as P53abn. Similarly, 204 tumors showed
- 204 MMRd, but of these 5 had a POLEmut. Thus, only 199 tumors were finally classified as
- 205 MMRd.
- 206 Double and triple classifiers influence the shift of cases between 2021 prognostic risk groups.
- 207 For example, as described above, a case can be placed in the P53abn classification group only
- if POLEmut and MMRd have been excluded. In this cohort, 10/594 (1.7%) had both a POLE
- and p53 mutation, of these 9/10 (90%) were FIGO stage I or II. Similarly, a case can be
- 210 placed in the MMRd classification group only if a POLEmut has been excluded. In this
- cohort, 2/594 (0.3%) had both a POLEmut and MMRd.

### 212 Assessment of prognosis

The 2021 molecular risk groups show a significant difference (all log rank p= 0.000) among the groups when considering recurrence free survival (RFS), disease specific survival (DSS) and overall survival (OS) (Figure 2).

216

## 217 Implementation of molecular diagnostics

218 For the 2021 molecular risk grouping, a shift upward is seen only in FIGO Stage I and II tumors

219 classified as P53abn. A shift downward was seen only in tumors classified as POLEmut.

220 Therefore, we tested a model where few supplementary diagnostic tests are applied.

In our study we have N=498, 83.3% with all FIGO Stage I and II tumors. In the low risk group with endometrioid Histology, no myometrial invasion, Grade 1or 2 and no LVSI no molecular analysis is needed, since even if they are P53abn the stay in low risk. In the endometrioid cohort therefore, in N=386 (65.0%) patients we need immunohistochemistry for p53. In cases showing an aberrant staining pattern (P53abn) (N=44, 7,4%), immunohistochemistry is needed for MMRd and sequencing for *POLE*mut, to allow correct molecular classification.

In order to identify high risk cases that might potentially be shifted downward due to *POLE* mut
classification, an additional 109 (18,4%) cases would need to be *POLE* sequenced.

Therefore, as summarized in Figure 3, in this population based cohort of patients with EC with N=594 patients, in 65% need a staining for P53, 7,4% for MMR Proteins and a total of N=153 (25.8%) need a sequencing for POLEmut (endometrioid and non-endometrioid) to allow a

233

232

#### 234 **DISCUSSION**

correct 2021 risk grouping.

In this study, we evaluate the implementation of the 2021 molecular ESGO/ESTRO/ESP prognostic risk groupings in an unselected cohort of endometrial cancer patients. We identify several areas where these groupings differ from their predecessor, and which may cause difficulty upon implementation.

We can confirm that, the implementation of the 2021 molecular prognostic groupings show significant differences in all survival outcomes, which proves the practicability of the new risk grouping. The last adaption with introduction of LVSI was performed 2016 showing similar results in stratifying the risk groups[23,24].

Implementation of the 2021 molecular risk groups on the cohort reveals several important aspects. First, not all P53abn cases are non endometrioid. Indeed, 26 endometrioid FIGO Grade 1 and 2 (low-grade) cases were identified, which would be improperly classified if molecular

246 markers had not been applied. Are all MMRd cases endometrioid? Even here, 29 MMRd cases 247 were judged to be non endometrioid. The results indicate that using histologic subtype to 248 attempt to "triage" cases to molecular subgroups may lead to significant problems with 249 classification and suggest that markers should be applied independent of histology, this was 250 also confirmed in the resent publication by Weigelt et al[25]. Applying TP53 251 immunohistochemistry on all cases of endometrioid FIGO 1 and 2 would represent a significant 252 change for most pathology labs[26]. In our cohort, fully one-third (26/80, 33%) of P53abn cases 253 would have been missed if endometrioid grade 1 and 2 cases were not stained. Similarly, 15% 254 (29/199) of MMRd cases would have been missed if only endometrioid cases were evaluated 255 for MMRd. Finally, it is important for labs to have access to *POLE* and MMR analyses, because 256 assignment to the TP53 molecular group should occur only if POLEmut and MMRd have been 257 excluded. Similarly, assignment to MMRd requires that a POLEmut has been excluded. In our 258 algorithm we could show, that not in all cases a molecular diagnostic is needed, rather only in 259 FIGO Stage I and II. By applying IHC for P53 in 65% and POLE sequencing in less than 20% 260 we found a model that is probably more practicable than performing a next generation 261 sequencing for all patients with EC.

262 Comparing the 2016 clinicopathologic and the 2021 molecular risk classification reveals 263 several interesting aspects. First, 8% of high-risk cases (12/145) downshifted to low-risk after 264 molecular classification due to POLEmut. These cases are specifically mentioned in the 265 recommendations as "rare", but in our cohort they represented the most prevalent reason for 266 risk group shifting [22,27]. In the PORTEC-3 trial, POLEmut stage 3 patients had an excellent 267 outcome, but all were treated with external beam radiotherapy. Second, 5% of low-risk cases 268 (12/235) shifted upward to high-risk after molecular classification, due to P53abn. Given that 269 low-risk disease is the most common, this means that potentially 1 out of 20 low-risk cases may 270 be misclassified, and subsequently undertreated, without molecular classification. Again,

PORTEC-3 indicates that combined therapy leads to a statistically significant survival
advantage for P53abn stage 1-3 [28]. Finally, note that the 2021 recommendations make a
difference between P53abn with and without myometrial invasion[1].

274 Should molecular evaluation be performed preoperatively? Studies have shown that molecular 275 markers performed upon biopsy material show similar results to those performed on 276 hysterectomy material [29]. Indeed, biopsy material can have the advantage of more rapid 277 fixation, potentially allowing for more reliable analysis. However, it is important to note that 278 the 2021 molecular risk groups cannot be determined using biopsy material alone, due to the 279 inclusion of clinicopathologic variables such as FIGO Stage and lymphovascular space 280 invasion. Thus, it is not clear that information beyond histologic tumor type and grade is 281 necessary.

Is it necessary to identify MMRd patients if it does not contribute to their risk grouping? There are several motivations for identifying MMRd patients beyond risk classification, including the desire to identify patients with Lynch syndrome. This is a worthy and important goal for reasons outlined in numerous publications[30,31]. However, from the standpoint of risk classification, MMRd is necessary to correctly classify patients as P53abn. It is important to keep the motivation for the testing clear, so that clinical genetics is consulted and involved in these changes in practice.

Evaluating the minimum testing regime necessary to correctly classify patients revealed that correct classification could be achieved in this cohort with 386/594 (65%) TP53 immunohistochemistry, 44/594 (7%) MMR immunohistochemistry, and 153 (26%) *POLE*mut analyses. Note that additional MMRd analyses may be useful for adjuvant therapy if immunotherapy is potentially indicated.

294

#### 295 CONCLUSION

296 The 2021 ESGO/ESTRO/ESP molecular risk groups represent a fundamental change in the 297 clinical diagnosis and treatment of endometrial cancer. Implementing and evaluating these 298 changes is a complex task that is only just beginning. Compared to the 2016 clinicopathologic 299 risk groups, 3.7% of high-risk patients were shifted downward to low-risk due to a POLE 300 mutation, and 2.9% of low-risk patients were shifted upward to high risk due to a P53abn 301 classification. It is possible to significantly reduce the number of analyses required to 302 implement the classification if resources are limited. Finally, it is important to note that the 303 P53abn group requires exclusion of POLEmut and MMRd, making it distinct from prior 304 descriptions of TP53 mutated tumors (where these exclusions were not made). Although no 305 cases were shifted upward or downward due to MMRd, this analysis is useful in identifying 306 women with Lynch syndrome or as a marker for immunotherapy.

307

308

#### **309** Conflict of interest statement

JWC has received funding from ThermoFisher Scientific / Affymetrix for a different study.
The authors have stated explicitly that there is otherwise no conflict of interest in connection
with this article.

313

#### 314 Authors' contributions:

315 SI, EE, DN, TTR and JWC designed the study protocol and data collection, FR, FS and SI

316 collected, cleaned and analysed the data, SI, DO, DN and JWC performed statistical analysis, MG

317 performed the molecular analysis and analysed the mutations, all authors drafted and revised the

318 paper.

319

# 321 **References**

- N. Concin, X. Matias-, I. Vergote, D. Cibula, M.R. Mirza, S. Marnitz, J. Ledermann, T.
  Bosse, C. Chargari, A. Fagotti, ESGO / ESTRO / ESP guidelines for the management
  of patients with endometrial carcinoma, (2021) 12–39. doi:10.1136/ijgc-2020-002230.
- 325 [2] N. Colombo, C. Creutzberg, F. Amant, T. Bosse, A. González-Martín, J. Ledermann,
- C. Marth, R. Nout, D. Querleu, M.R. Mirza, C. Sessa, ESMO-ESGO-ESTRO
   Endometrial Consensus Conference Working Group, ESMO-ESGO-ESTRO
   Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.,
- 329 Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27 (2016) 16–41.
- doi:10.1093/annonc/mdv484.
- S. Bendifallah, G. Canlorbe, P. Collinet, E. Arsène, F. Huguet, C. Coutant, D. Hudry,
  O. Graesslin, E. Raimond, C. Touboul, E. Daraï, M. Ballester, Just how accurate are
  the major risk stratification systems for early-stage endometrial cancer?, Br. J. Cancer.
  112 (2015) 793–801. doi:10.1038/bjc.2015.35.
- S. Bendifallah, G. Canlorbe, E. Raimond, D. Hudry, C. Coutant, O. Graesslin, C.
  Touboul, F. Huguet, A. Cortez, E. Daraï, M. Ballester, A clue towards improving the
  European Society of Medical Oncology risk group classification in apparent early stage
  endometrial cancer? Impact of lymphovascular space invasion, Br. J. Cancer. 110
  (2014) 2640–2646. doi:10.1038/bjc.2014.237.
- T.W. Kong, S.-J. Chang, J. Paek, Y. Lee, M. Chun, H.-S. Ryu, Risk group criteria for
  tailoring adjuvant treatment in patients with endometrial cancer: a validation study of
  the Gynecologic Oncology Group criteria, J. Gynecol. Oncol. 26 (2015) 32.
  doi:10.3802/jgo.2015.26.1.32.
- Cancer Genome Atlas Research Network, C. Kandoth, N. Schultz, A.D. Cherniack, R.
  Akbani, Y. Liu, H. Shen, A.G. Robertson, I. Pashtan, R. Shen, C.C. Benz, C. Yau,
  P.W. Laird, L. Ding, W. Zhang, G.B. Mills, R. Kucherlapati, E.R. Mardis, D.A.
  Levine, Integrated genomic characterization of endometrial carcinoma., Nature. 497
  (2013) 67–73. doi:10.1038/nature12113.
- A. Talhouk, M.K. McConechy, S. Leung, W. Yang, A. Lum, J. Senz, N. Boyd, J. Pike,
  M. Anglesio, J.S. Kwon, A.N. Karnezis, D.G. Huntsman, C.B. Gilks, J.N. McAlpine,
  Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial
  cancer, Cancer. 123 (2017) 802–813. doi:10.1002/cncr.30496.
- A. Talhouk, L.N. Hoang, M.K. McConechy, Q. Nakonechny, J. Leo, A. Cheng, S.
  Leung, W. Yang, A. Lum, M. Köbel, C.H. Lee, R.A. Soslow, D.G. Huntsman, C.B.
  Gilks, J.N. McAlpine, Molecular classification of endometrial carcinoma on diagnostic
  specimens is highly concordant with final hysterectomy: Earlier prognostic information
  to guide treatment, Gynecol. Oncol. 143 (2016) 46–53.
  doi:10.1016/j.ygyno.2016.07.090.
- A.N. Karnezis, S. Leung, J. Magrill, M.K. McConechy, W. Yang, C. Chow, M. Kobel,
  C.-H. Lee, D.G. Huntsman, A. Talhouk, F. Kommoss, C.B. Gilks, J.N. McAlpine,
  Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the
  context of molecular classification, J. Pathol. Clin. Res. 3 (2017) 279–293.
  doi:10.1002/cjp2.82.
- A. Talhouk, M.K. McConechy, S. Leung, H.H. Li-Chang, J.S. Kwon, N. Melnyk, W.
  Yang, J. Senz, N. Boyd, A.N. Karnezis, D.G. Huntsman, C.B. Gilks, J.N. McAlpine, A
  clinically applicable molecular-based classification for endometrial cancers, Br. J.
  Cancer. 113 (2015) 299–310. doi:10.1038/bjc.2015.190.
- 368 [11] S. Kommoss, M.K. McConechy, F. Kommoss, S. Leung, A. Bunz, J. Magrill, H.
  369 Britton, F. Kommoss, F. Grevenkamp, A. Karnezis, W. Yang, A. Lum, B. Krämer, F.

370 371 372 373		Taran, A. Staebler, S. Lax, S.Y. Brucker, D.G. Huntsman, C.B. Gilks, J.N. McAlpine, A. Talhouk, Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series., Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. (2018). doi:10.1093/annonc/mdv058.
374 375 376	[12]	L. Vermij, V. Smit, R. Nout, T. Bosse, Incorporation of molecular characteristics into endometrial cancer management, Histopathology. 76 (2020) 52–63. doi:10.1111/bis.14015
377 378 379 380	[13]	E. Stelloo, T. Bosse, R.A. Nout, H.J. Mackay, D.N. Church, H.W. Nijman, A. Leary, R.J. Edmondson, M.E. Powell, E.J. Crosbie, H.C. Kitchener, L. Mileshkin, P.M. Pollock, V.T. Smit, C.L. Creutzberg, Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: A TransPORTEC initiative Mod Pathol
381 382	[14]	<ul><li>28 (2015) 836–844. doi:10.1038/modpathol.2015.43.</li><li>J. McAlpine, A. Leon-Castillo, T. Bosse, The rise of a novel classification system for</li></ul>
383 384 285	[17]	endometrial carcinoma; integration of molecular subclasses, J. Pathol. (2018). doi:10.1002/path.5034.
385 386 387	[15]	J.W. Carlson, Phenotype of POLE-mutated endometrial cancer, PLoS One. (2019). doi:10.1371/journal.pone.0214318.
388 389	[16]	E. Oliva, A. Cheung, S. Lax, WHO Classification of Tumours of the Female Genital Tract, 2020.
390 391 392	[17]	N. Colombo, E. Preti, F. Landoni, S. Carinelli, A. Colombo, C. Marini, C. Sessa, Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 24 (2013) doi:10.1093/annonc/mdt353
393 394	[18]	D.N. Church, E. Stelloo, R.A. Nout, N. Valtcheva, J. Depreeuw, N. ter Haar, A. Noske, F. Amant, I.P.M.M. Tomlinson, P.J. Wild, D. Lambrechts, I.M. Jürgenliemk-Schulz,
395 396 397		J.J. Jobsen, V.T.H.B.M. Smit, C.L. Creutzberg, T. Bosse, Prognostic significance of POLE proofreading mutations in endometrial cancer., J. Natl. Cancer Inst. 107 (2015) 402 doi:10.1093/inci/diu402
398 399	[19]	E. Stelloo, R.A.A. Nout, E.M.M. Osse, I.J. Ju rgenliemk-Schulz, J.J.J. Jobsen, L.C.C. Lutgens, E.M.M. van der Steen-Banasik, H.W.W. Nijman, H. Putter, T. Bosse, C.L.L.
400 401 402		Creutzberg, V.T.H.B.M.T.H.B.M. Smit, I.J. Jürgenliemk-Schulz, J.J.J. Jobsen, L.C.C. Lutgens, E.M.M. van der Steen-Banasik, H.W.W. Nijman, H. Putter, T. Bosse, C.L.L. Creutzberg, V.T.H.B.M.T.H.B.M. Smit, Improved risk assessment by integrating
403 404 405		molecular and clinicopathological factors in early-stage endometrial cancer - combined analysis of PORTEC cohorts, Clin. Cancer Res. 22 (2016). doi:10.1158/1078-0432.CCR-15-2878.
406 407	[20]	C.M. Cosgrove, D.L. Tritchler, D.E. Cohn, D.G. Mutch, C.M. Rush, H.A. Lankes, W.T. Creasman, D.S. Miller, N.C. Ramirez, M.A. Geller, M.A. Powell, F.J. Backes,
408 409 410		L.M. Landrum, C. Timmers, A.A. Suarez, R.J. Zaino, M.L. Pearl, P.A. DiSilvestro, S.B. Lele, P.J. Goodfellow, P. Goodfellow, An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer HHS
411 412	[21]	Public Access, Gynecol Oncol. 148 (2018) 174–180. doi:10.1016/j.ygyno.2017.10.037. E. Stelloo, T. Bosse, R.A. Nout, H.J. MacKay, D.N. Church, H.W. Nijman, A. Leary,
413 414 415		R.J. Edmondson, M.E. Powell, E.J. Crosbie, H.C. Kitchener, L. Mileshkin, P.M. Pollock, V.T. Smit, C.L. Creutzberg, Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative. Mod. Pathol. 28
416 417	[22]	<ul><li>(2015) 836–844. doi:10.1038/modpathol.2015.43.</li><li>A. León-Castillo, H. Britton, M.K. McConechy, J.N. McAlpine, R. Nout, S. Kommoss,</li></ul>
418 419		S.Y. Brucker, J.W. Carlson, E. Epstein, T.T. Rau, T. Bosse, D.N. Church, C.B. Gilks, Interpretation of somatic POLE mutations in endometrial carcinoma., J. Pathol. 250

420 (2020) 323-335. doi:10.1002/path.5372. 421 S. Bendifallah, L. Ouldamer, V. Lavoue, G. Canlorbe, E. Raimond, C. Coutant, O. [23] 422 Graesslin, C. Touboul, P. Collinet, E. Daraï, M. Ballester, Patterns of recurrence and 423 outcomes in surgically treated women with endometrial cancer according to ESMO-424 ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN 425 study Group, Gynecol. Oncol. 144 (2017) 107–112. doi:10.1016/j.ygyno.2016.10.025. 426 N. Colombo, C. Creutzberg, F. Amant, T. Bosse, A. González-Martín, J. Ledermann, [24] 427 C. Marth, R. Nout, D. Querleu, M.R. Mirza, C. Sessa, ESMO-ESGO-ESTRO 428 Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up, 429 Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27 (2016) 16-41. 430 doi:10.1093/annonc/mdv484. 431 A. Da, C. Paula, D.F. Delair, L. Ferrando, D.J. Fix, R.A. Soslow, K.J. Park, S. Chiang, [25] 432 J.S. Reis-filho, A. Zehir, M.T.A. Donoghue, M. Wu, D.N. Brown, R. Murali, C.F. 433 Friedman, D. Zamarin, V. Makker, J.J. Mueller, M.M. Leitao, N.R. Abu-rustum, C. 434 Aghajanian, B. Weigelt, Gynecologic Oncology Genetic and molecular subtype 435 heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer, 436 Gynecol. Oncol. (2021). doi:10.1016/j.ygyno.2021.02.015. 437 A. Manuscript, P. Onlinefirst, Downloaded from clincancerres.aacrjournals.org on [26] 438 March 11, 2021. © 2021 American Association for Cancer Research., (2021). 439 doi:10.1158/1078-0432.CCR-20-4436. D.N. Church, E. Stelloo, R.A. Nout, N. Valtcheva, J. Depreeuw, N. Ter Haar, A. 440 [27] 441 Noske, F. Amant, I.P.M. Tomlinson, P.J. Wild, D. Lambrechts, I.M. J?rgenliemk-442 Schulz, J.J. Jobsen, V.T.H.B.M. Smit, C.L. Creutzberg, T. Bosse, Prognostic 443 significance of POLE proofreading mutations in endometrial cancer, J. Natl. Cancer 444 Inst. 107 (2015). doi:10.1093/jnci/dju402. 445 S.M. De Boer, M.E. Powell, L.R. Mileshkin, H.J. Mackay, A. Leary, H.W. Nijman, N. [28] 446 Singh, P.M. Pollock, P. Bessette, A. Fyles, C. Haie-meder, V.T.H.B.M. Smit, R.J. 447 Edmondson, H. Putter, H.C. Kitchener, E.J. Crosbie, M. De Bruyn, R.A. Nout, N. 448 Horeweg, C.L. Creutzberg, T. Bosse, Molecular Classi fi cation of the PORTEC-3 449 Trial for High-Risk Endometrial Cancer : Impact on Prognosis and Bene fi t From 450 Adjuvant Therapy abstract, 38 (2021). doi:10.1200/JCO.20.00549. 451 A. Talhouk, L.N. Hoang, M.K. Mcconechy, Q. Nakonechny, J. Leo, A. Cheng, S. [29] 452 Leung, W. Yang, A. Lum, M. Köbel, C.-H. Lee, R.A. Soslow, D.G. Huntsman, C.B. 453 Gilks, J.N. Mcalpine, Molecular classification of endometrial carcinoma on diagnostic 454 specimens is highly concordant with final hysterectomy: Earlier prognostic information 455 to guide treatment, Gynecol. Oncol. 143 (2016) 46-53. 456 doi:10.1016/j.ygyno.2016.07.090. 457 A.M. Mills, E.A. Sloan, M. Thomas, S.C. Modesitt, M.H. Stoler, K.A. Atkins, C.A. [30] 458 Moskaluk, Clinicopathologic Comparison of Lynch Syndrome - associated and " 459 Lynch-like "Endometrial Carcinomas Identified on Universal Screening Using 460 Mismatch Repair Protein Immunohistochemistry, 40 (2016) 155–165. 461 C. Stinton, H. Fraser, L. Al-khudairy, R. Court, M. Jordan, D. Grammatopoulos, S. [31] 462 Taylor-phillips, Gynecologic Oncology Testing for lynch syndrome in people with 463 endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies – A systematic review of test accuracy, Gynecol. Oncol. 160 (2021) 464 465 148-160. doi:10.1016/j.ygyno.2020.10.003. 466 467

# 468 Figures and table legends

- 469 Table 1. Patient characteristics with molecular markers, demographic, and clinicopathologic470 factors.
- 471 **Table 2.** Shifting upward and downward of cases between the 2016 and the 2021 molecular
- 472 risk groups. The cross table reveals a significant change in the prognostic groups, (p=0,000
- 473 Chi-square).

#### 474 Figure 1. Change between the old and new risk classification

- 475 The shift of patients between prognostic risk groups, as well as the distribution of the
- 476 molecular subtypes within the prognostic groups. Red arrow: p53abn, green: POLEmut
- 477

#### 478 Figure 2. Kaplan-Meier survival curves for PFS for molecular subgroups. Kaplan-Meier

- 479 curves with log-rank test demonstrating the prognosis of patients stratified using the 2021
- 480 ESGO/ESTRO/ESP molecular prognostic groups compared to the prior clinicopathologic
- 481 only risk groups. Comparison performed showing Progression free survival (PFS), Disease
- 482 specific survival (DSS) and overall survival (OS).
- 483

#### 484 Figure 3. Flow chart with selective analysis for molecular testing

485 Flow chart, which shows how the patients can be triaged to allow testing for P53, MMR or

486 POLE only when indicated.

Variable			Mo	lecular clas	sifier	
	Total	MMRd	<b>POLE</b> mut	P53adn	NSMP	p-value
	N (%)					association
No. Of patients	594 (100)	199 (33.5)	38 (6.4)	86 (14.5)	271 (45.6)	
(%)	0) (100)	133 (00.0)		00(1.10)	_// (.0.0)	
Age						P=0.001
$Mean \pm SE$	66±0.4	67.2±0.7	60.1±1.4	67±1	65.8±0.6	
Median	67	68	60.5	67	66	
BMI mean±SE	29.1±0.3	28.5±0.5	27.3±1.0	29.3±0.9	29.7±0.5	<i>p</i> =0.68
Missing	106	35	2	18	51	^
Grade (%)						<i>p</i> =0.00
G1	226 (38.0)	59 (29.6)	13 (34.2)	14 (16.3)	140 (51.7)	
G2	202 (34.0)	88 (44.2)	9 (23.7)	12 (13.9)	93 (34.3)	
G3	166 (27.9)	52 (26.1)	16 (42.1)	60 (69.8)	38 (14.0)	
Histotype						<i>p</i> =0.00
Non-endo	100 (16.8)	29 (14.6)	7 (18.4)	48 (55.8)	16 (5.9)	
Endometrioid	494 (83.2)	170 (85.4)	31 (81.6)	38 (44.2)	255 (94.1)	
LVSI						<i>p</i> =0.00
Yes	161 (27.1)	62 (31.2)	15 (39.5)	34 (39.5)	50 (18.5)	
No	433 (72.9)	137 (68.8)	23 (60.5)	52 (60.5)	221 (81.5)	
FIGO Stage						<i>p</i> =0.00
	443 (74.6)	147 (73.9)	33 (86.8)	49 (57.0)	214 (79.0)	
	55 (9.3)	21 (10.6)	2 (5.2)	9 (10.5)	23 (8.5)	
	69 (11.6)	27 (13.6)	3 (7.9)	14 (16.3)	25 (9.2)	
IV Marcana Antal	27 (4.5)	4 (2.0)	0(0)	14 (16.3)	9 (3.3)	0.00
Myometrial						<i>p</i> =0.08
invasion intramucoccel	52 (8 0)	16 (2 0)	1 (2.6)	4 (4 7)	22(11.8)	
	33(6.9) 305(51.3)	10(6.0) 100(50.3)	1(2.0) 23(605)	4(4.7)	32(11.0) 1/3(52.8)	
<50%	235 (39.6)	100(30.3) 82(41.2)	14(36.8)	<u> </u>	96(354)	
Missing	1(02)	1(0.5)	0	0	0	
I vmnh node	1 (0.2)	1 (0.5)	0	0	0	
status	323	84 (31 3)	22 (8 2%)	51(19.0)	111(41.1)	n=0.01
LN removed	63 (10.6)	20(101)	2(53)	17 (19.8)	24 (8 9)	p = 0.01 p = 0.20
Pos	236 (39.7)	76 (38.2)	21 (55.3)	41 (47.7)	98 (36.2)	p 0.20
Neg						
Adjuvant treat	242 (57 ()	111 (55.9)	22 (57.0)	28 (22 ()	101 (66.0)	<i>p</i> =0.00
NO Vos	342 (57.0)	111(55.8)	22(57.9)	28 (32.0)	181(00.8)	
Missing	239(40.2) 13(2.2)	8 (4 0)	10(42.1)	$\frac{37(00.2)}{1(1.2)}$	4(15)	
wiissing	13 (2.2)	8 (4.0)	0(0)	1 (1.2)	4 (1.3)	
Recurrence						
Yes	88 (14.8)	29 (14.6)	1 (2.6)	26 (30.2)	32 (11.8)	<i>p</i> =0.00
No	470 (79.1)	152 (76.3)	36 (94.7)	58 (67.4)	224 (82.7)	
Missing	36 (6.1)	18 (9.0)	1 (2.6)	2 (2.3)	15 (5.5)	
Survival			1			
Alive	486 (82.1)	162 (81.4)	37 (97.4)	60 (69.7)	227 (83.8)	<i>p</i> =0.00
DOD	57 (9.6)	15 (7.5)	1 (2.6)	21 (24.4)	20 (7.4)	
Other cause	28 (4.7)	9 (4.5)	0	3 (3.5)	16 (5.9)	
Unknown cause	15 (2.5)	9 (4.5)	0		6 (2.2)	
Treatment	3 (0.5)	1 (0.5)	0	2 (2.3)	0	
Missing	3(0.5)	3 (1.5)	0	0	2 (0.7)	

Table 1. Association between molecular markers, demographic and clinicopathologic factors.

Table 2. Shifting upward and downward of cases between the 2016 and the 2021 molecular risk groups.

			2016 Clinico	pathologic <b>R</b>	isk Groups		
SP ps		Low risk	Intermed risk	High- intermed risk	High risk	Advanced / metastatic	Total
0ul	Low risk	221	1	9	12	0	243
STRC sk Gr	Intermed risk	2	82	0	0	0	84
SGO/E cular Ri	High- intermed risk	0	0	89	0	0	89
11 I ole	High risk	12	1	2	133	0	148
202 M	Advanced / metastatic	0	0	0	0	30	30
	Total	235	84	100	145	30	594

Risk group	2016 Cpath Only	PSSabii	202	1 Molecular
Low	N=235	N=2	N=1	43 MMRd: 71 TP53abn: 0 NSMD: 137
Intermediate	N=84	N=12	N=9 N=8	POLEmut: 0 4 MMRd: 27 TP53abn: 3 NSMD: 54
High-intermediate	N=100	N=1 N=2	N=8	POLEmut: 0 9 MMRd: 53 TP53abn: 0 NSMD: 36
High	N=145	_	N=1	48 MMRd: 42 TP53abn: 68 NSMD: 35
Advanced	N=30		N=3	POLEmut: 0 0 MMRd: 6 TP53abn: 15 NSMD: 9



# Disease FIGO stage I+II (n=498)



# **Highlights:**

- Application of the 2021 ESGO/ESTRO/ESP molecular risk groups is feasible and shows significant differences in survival.
- Immunochemistry for TP53 and MMR and applying POLE sequencing is only needed in selected cases.
- The shift in the risk groups are done by P53and and POLEmut classifications in a sizeable number of patients.